6/29/23, 1:42 AM POSEIDON (chemotherapy plus durvalumab) Pathway Feedback Search Clinical Topics Home Studies POSEIDON (chemotherapy plus durvalumab) POSEIDON (chemotherapy plus durvalumab) Disease Non-small cell lung cancer Trial question What is the role of first-line durvalumab plus chemotherapy in patients with metastatic non-small cell lung cancer? Study design Multi-center Open label RCT Population Characteristics of study participants 26.0% female N = 675 74.0% male 675 patients (174 female, 501 male) Inclusion criteria: adult patients with epidermal growth factor receptor/ALK wild-type metastatic non-small cell lung cancer Key exclusion criteria: mixed small cell lung cancer and non-small cell lung cancer histology; autoimmune or inflammatory disorders; brain metastases or spinal cord compression; active infection Interventions N=338 durvalumab plus chemotherapy (at a dose of 1500 mg and platinum-based chemotherapy for up to four 21-day cycles, followed by durvalumab once every 4 weeks until progression) https://web.pathway.md/studies/rec37I5uhTQ6CL2y7 1/2 6/29/23, 1:42 AM POSEIDON (chemotherapy plus durvalumab) Pathway N=337 chemotherapy (chemotherapy for up to six 21-day cycles with or without maintenance pemetrexed) Primary outcome Progression-free survival 5.5 months 5.5 4.8 4.1 months 2.8 months 1.4 months Significant increase 0.0 months Durvalumab plus chemotherapy Chemotherapy Significant increase in progression-free survival (5.5 months vs. 4.8 months; HR 1.35, 95% CI 1.12 to 1.61) Secondary outcomes No significant difference in overall survival (13.3 months vs. 11.7 months; HR 1.16, 95% CI 0.98 to 1.38) Borderline significant increase in unconfirmed objective response rate (48.5% vs. 33.4%; OR 1.9, 95% CI 1.38 to 2.62) Safety outcomes No significant difference in adverse events; grade 3/4 treatment-related adverse events. Conclusion In adult patients with epidermal growth factor receptor/ALK wild-type metastatic non-small cell lung cancer, durvalumab plus chemotherapy was superior to chemotherapy with respect to a progression-free survival. Reference Melissa L Johnson, Byoung Chul Cho, Alexander Luft et al. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small- Cell Lung Cancer: The Phase III POSEIDON Study. J Clin Oncol. 2022 Nov 3;JCO2200975. Open reference URL https://web.pathway.md/studies/rec37I5uhTQ6CL2y7 2/2